INTRODUCTION
Cytotoxic chemotherapy remains the main treat ment for malignant tumors. Renal failure is one of the serious adverse reactions caused when chemotherapeutical agents are ad min istered, since the majority of anticancer drugs are excreted through the kidneys. When the creatinine/glo merular filtrat ion data (GFR) is higher than normal, chemotherapy involving almost all cytotoxic agents is avoided, or the dosage is reduced. The main agent accompanied by renal failure is cisplatin (CDDP); it has been in use for over 30 years and has been shown to be quite an effective agent in a great number of malignancies, such as lung, ovarian, head and neck, urethral and testicular cancers. [1] [2] [3] [4] [5] [6] [7] [8] [9] Cisplatin is one of the most important anticancer drugs with respect to effectiveness, but its toxicity is often an inhibitory factor. The main side effect is renal to xicity (renal failure). Other adverse reactions are nausea/vomit ing, fatigue and neurotoxicity. [10] [11] [12] [13] Over the last decades, there has been an extensive effort to substitute other agents for CDDP. The cisplatin analogue, carboplatin, has been the drug main ly used, instead of cisplatin, for several malignant tumors . Taxanes (paclitaxel, docetaxel), gemcitabine and vinorelbine have also been tested in several malignancies such as non-small-cell lung cancer (NSCLC) and ovarian cancer. With the aforementioned agents, renal toxicity was avoided but other side effects such as myelotoxicity were observed. None of these drugs, however, were better than or equal to cisplatin in effectiveness. [14] [15] [16] [17] [18] [19] [20] Liposomal cisplatin is new formulat ion of cisplatin which was produced some years ago. The main scope of this new agent was to reduce the nephrotoxicity caused by cisplatin, to avoid other adverse reactions and certainly to be effective. Up until now, there have been more than 16 studies (preclin ical and clinical) published on liposomal cisplatin (lipoplatin). It has been tested in pancreatic cancer, in NSCLC, in breast and in head and neck cancers. In the majority of tumors tested, it has been as equally effective as cisplatin and much less toxic. [21] [22] [23] [24] [25] [26] [27] [28] A recent study examined the effectiveness of lipoplatin versus cisplatin, each combined with paclitaxel, in adenocarcinoma of the lungs. It was found that the response rate was statistically significantly higher, in favour of lipoplatin Arm. 29 The primary object ive of the present study was to investigate the administration of lipoplatin in patients with renal insufficiency and secondly, to determine the response of patients with bladder cancer, the majority of whom received the present treatment as first-line therapy.
MATERIALS AND METHODS

Eligibility criteria
Patients >18 years of age with a histologically-or cytologically-confirmed d iagnosis of malignant disease, who were pretreated or who were chemotherapy-and radiotherapy-naïve, were enrolled in the study. Other elig ibly criteria included a World Health Organisation (WHO) performance status (PS) of 0-2, life expectancy of at least 3 months, adequate bone marrow reserve (granulocyte count 1500μl -1 , platelet count 120000/μl -1 ), normal liver function and normal cardiac function with no history of clinically unstable angina pectoris or myocardial infarction or congestive heart failure within the 6 months prior. Patients with central nervous system involvement were elig ible if they were asymptomat ic. Patients with active infection, malnutrition or a second primary tumor were excluded fro m the study. Having had the experience fro m previous studies that liposomal
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The study was approved by our institutional review board and all patients gave their written info rmed consent to participate.
Treatment pl an
All patients were treated on an outpatient basis. Five patients were init ially treated with lipoplatin monotherapy once every 2 weeks at a dose of 150-200 mg/ m 2 . Upon finding that no side effects were observed and there was no increase in serum creatin ine, we started the treatment in comb ination with gemcitabine at a dose 1000 mg/ m 2 , for the patients with bladder cancer. The treat ment was repeated every 2 weeks. Lipoplat in was infused for 8 hours and gemcitabine for 90 minutes; lung cancer patients received paclitaxel at a dose of 175 mg/ m 2 for 3 hours, and lipoplatin as above; patients with gastrointestinal tract cancer received 700 mg/ m 2 of 5-fluorouracil (5-FU) and 200 mg of leucovorin, for 2 hours and lipoplatin as above. Premed ication involved dexamethasone (8 mg) and both H1 and H2 receptor antagonists to prevent hypersensitivity reactions. All agents were given on day 1. Dose adjustment criteria were based on hematological and renal parameters. In cases of grade 3 and 4 febrile neutropenia, we decided we would reduce all drug doses by 25% in the subsequent cycles and rhG-CSF was then to be admin istered. Toxicities were graded according to the WHO guidelines . 30 Pretreat ment evaluation included medical history and physical examination, full blood count including differential leukocyte and platelet counts, a standard biochemical profile, electrocardiogram, X-rays of the chest, ultrasound of the upper abdomen and computed tomography (CT) scans of the chest, upper and lower abdomen. Additional imaging studies were performed upon clinical indication. Full blood counts with differential were performed weekly. In cases of grade 3 and 4 neutropenia or thrombocytopenia, full blood counts were to be evaluated daily.
A detailed med ical and physical examination was completed before each course of treat ment (once every 2 weeks), in o rder to document the symptoms of the disease and treatment toxicit ies. CT scans were performed every 3 cycles (once every 6 weeks).
Definiti on for response
For the assessment of response, we used imag ing-based evaluation. A comp lete response (CR) was considered to be the disappearance of all measurable disease confirmed at 4 weeks at the earliest; a partial response (PR), a 30% decrease, also confirmed at 4 weeks at the earliest. In stable disease (SD), neither the PR nor the progressive disease (PD) criteria were met; PD was considered to be a 20% increase of tumor burden and no CR, PR or SD documented before increased disease. Res ponse data were based on the response evaluation criteria in solid tumors (RECIST). 31 A two-step deterioration in performance status, a >10% loss in pretreatment weight or increasing symptoms did not by themselves constitute progression of the disease; however, the appearance of these complaints was followed by a new evaluation of the extent of the disease. All responses had to be maintained for at least 4 weeks and be confirmed by an independent panel of radiologists.
Statistical design
Simon's two stage minimax design was used for calculation of the sample size. The significance level was set to be 5% and the power 90%. Lo w response probability was set to be 20% and the level of useful activity 40%. In the first stage, 20 patients were enro lled in the study. If 5 or fewer responses had been observed, then the study would have been terminated. Otherwise, if more than 5 responses were observed, another 20 patients would be recruited for a maximu m sample size of 40 patients.
RES ULTS
Fro m June 2006 till Augus t 2011, 42 patients were enrolled in this one-clinic trial. All were evaluable for toxicity and response. The 16 patients with bladder cancer had renal insufficiency; 14 of these patients received lipoplatin and gemcitabine treat ment as a first-line chemotherapy and 2 as second-line therapy. Sixteen other patients with NSCLC (14 with adenocarcinoma, 2 with squamous cell carcino ma ) received lipoplatin plus paclitaxel as second-or third-line treat ment. The 10 patients with gastrointestinal cancer received lipoplatin-5-FU-leucovorin as second-line or third-line treatment. There were 40 males and 2 females (med ian age 65y range 49-84y). Fourteen patients with bladder cancer had limited disease, whereas the remain ing 28 enro lled patients had advanced (Table 1) . At the end of the study, 11 patients were still alive. Two hundred and two chemotherapy cycles were administered (median 6 cycles, range 2-12). Twelve cycles were given to one patient during two different time periods. Treatment was delayed for one week in 4 patients; this delay was due to non-renal to xicity i.e. to the myeloto xicity produced by the second cytotoxic agent. There was no need to reduce the dose of lipoplatin but only that of the second cytotoxic agent, by 25%. At the time of analysis, 11 patients (26.19%) were still alive. The cause of death for the remaining patients was the disease (mainly NSCLC), and heart attack or brain metastasis.
Response to treatment and survi val
Survival was evaluated on an intention-to-treat basis. Table 2 ). The median duration of response was in total 7 months (range 3-11 months). Of the 16 patients with bladder cancer the median duration of response was 12 months (range 4-18 months). One patient with bladder cancer who had achieved a complete response, had a tumor recurrence after 12 months; he survived for 48 months and died of a heart attack. All 42 patients were evaluable for to xicity. The treat ment caused no renal toxicity; there was no increase in blood urea and serum creatinine and in some patients there was a reduction in these levels. In 10/16 patients with bladder cancer, the blood urea and serum creatin ine levels decreased, towards normal levels; this reduction was observed in these patients who had had a u rination obstruction, which after treat ment returned to normal. Grade 1-2 nausea/vomit ing was observed in 8 (19.05%) patients. Myelotoxicity was observed in 12 (28.57%) patients; this was attributed to the second agent given in combination with lipoplatin. Grade 1-2 anemia was observed in half of the patients. Grade 1-2 peripheral neuropathy was observed in 13 patients who received paclitaxel as the second agent. Mild fatigue was also observed in the majority of patients (Table 3) . 
DISCUSS ION
Liposomal cisplatin (lipoplatin ) is a new agent which could become a substitute for cisplatin. There are more than 16 trials concerning lipoplatin and it has shown equal effectiveness to cisplatin and a better response rate with a statistically significant difference (lipoplatin versus cisplatin) in adenocarcino ma of the lungs. 32 The most important parameter with regard to lipoplatin and part of its effectiveness is the lack of adverse reactions: in particular, there is no renal to xicity. Th is is due to the low excretion of the drug, through the kidneys (40% renal excretion in 3 days). 32 It is not only this lack of renal toxicity but the fact that one can infuse this agent for 8 hours in patients who already have renal toxicity. There are quite a number of patients with blood urea and serum creatinine at abnormally high levels where the administration of anticancer drugs is impossible with the proper (maximu m tolerated dose); common treat ment involves a combination of anticancer agents in order to achieve a better response. Lipoplatin may favorably be considered as the treatment solution for cancer patients with renal insufficiency. To date, the trials on lipoplatin have shown that it can be used as a substitute for cisplatin in adenocarcinoma of the lungs, in pancreatic and bladder cancer; in the future, it might be administred for other tumors, such as ovarian cancer, gynaecological malignancies, esophageal and gastric cancers.
In the present study, lipoplatin has shown effectiveness without toxicity proble ms in patients with renal failure. It has been tested in NSCLC, in gastrointestinal and in bladder cancer. Future trials may confirm the present data and be a cause for courage for certain groups of cancer patients.
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